Loading clinical trials...
Loading clinical trials...
A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria: a Randomized Double Blind Cross-Over Trial
Conditions
Interventions
Zibotentan
Dapagliflozin
+2 more
Locations
7
United States
Anschutz Medical Campus
Aurora, Colorado, United States
Toronto General Hospital
Toronto, Ontario, Canada
Montreal Clinical Research Institute
Montreal, Quebec, Canada
Steno Diabetes Center
Copenhagen, Gentoft, Denmark
Amsterdam Universitair Academisch Centrum
Amsterdam, North Holland, Netherlands
University Medical Center Groningen
Groningen, Netherlands
Start Date
October 6, 2022
Primary Completion Date
March 5, 2025
Completion Date
March 5, 2025
Last Updated
April 30, 2025
NCT05728216
NCT04592640
NCT07094906
NCT07358572
NCT05099770
NCT06927024
Lead Sponsor
University Medical Center Groningen
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions